Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

by Osinusi, Anu , Marty, Francisco M , Ryan, Pablo , Katz, Morgan J , Webb, Brandon J , Schiffer, Joshua T , Juneja, Kavita , Sachdeva, Yessica , Chen, Shuguang , Abdelghany, Mazin , Gottlieb, Robert L , Oguchi, Godson , Nielsen, Bibi U , Hidalgo, Ausberto , Paredes, Roger , Mera, Jorge , Osiyemi, Olayemi , Vaca, Carlos E , Brown, Michael , Mittal, Shilpi , Hyland, Robert H , Duff, Frank , Perez, Gilberto , Camus, Gregory , Hill, Joshua A , Ginde, Adit A , Behenna-Renton, Nicole , Skarbinski, Jacek , Davies, Santosh , Brown, Samuel M

in Adenosine Monophosphate - adverse effects / Adenosine Monophosphate - analogs & derivatives / Adenosine Monophosphate - therapeutic use / Adult / Adverse events / Age / Aged / Aged, 80 and over / Alanine - adverse effects / Alanine - analogs & derivatives / Alanine - therapeutic use / Antiviral Agents - adverse effects / Antiviral Agents - therapeutic use / Antiviral drugs / Clinical trials / Comorbidity / Confidence intervals / Coronavirus / Coronaviruses / COVID-19 / COVID-19 - complications / COVID-19 - drug therapy / COVID-19 - mortality / Death / Diabetes / Diabetes mellitus / Disease Progression / Double-Blind Method / Double-blind studies / Enrollments / Female / Hospitalization / Hospitalization - statistics & numerical data / Humans / Infectious Disease / Influenza / Intravenous administration / Male / Middle Aged / Monoclonal antibodies / Mortality / Nursing / Obesity / Original / Outpatients / Patients / Placebos / Questionnaires / Risk factors / RNA polymerase / SARS-CoV-2 - drug effects / Severe acute respiratory syndrome coronavirus 2 / Statistical analysis / Time-to-Treatment / Viral infections / Viral Load

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

2022

Confirm

Do you wish to request the book?

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Osinusi, Anu,

Marty, Francisco M,

Ryan, Pablo,

Katz, Morgan J,

Webb, Brandon J,

Schiffer, Joshua T,

Juneja, Kavita,

Sachdeva, Yessica,

Chen, Shuguang,

Abdelghany, Mazin,

Gottlieb, Robert L,

Oguchi, Godson,

Nielsen, Bibi U,

Hidalgo, Ausberto,

Paredes, Roger,

Mera, Jorge,

Osiyemi, Olayemi,

Vaca, Carlos E,

Brown, Michael,

Mittal, Shilpi,

Hyland, Robert H,

Duff, Frank,

Perez, Gilberto,

Camus, Gregory,

Hill, Joshua A,

Ginde, Adit A,

Behenna-Renton, Nicole,

Skarbinski, Jacek,

Davies, Santosh,

Brown, Samuel M

2022

Overview

Among nonhospitalized patients with Covid-19–related symptoms that began less than a week previously, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. Adverse effects in the remdesivir group were similar to those in the placebo group.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adenosine Monophosphate - adverse effects

/ Adenosine Monophosphate - analogs & derivatives

/ Adenosine Monophosphate - therapeutic use

/ Adult

/ Adverse events

/ Age

/ Aged